Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers determine two arthritis medications are safe and effective for children

21.04.2005


An international team of researchers, led by Dr. Earl Silverman of The Hospital for Sick Children (Sick Kids), has found that two arthritis medications (methotrexate and leflunomide) commonly used in adults are safe and effective in children. This research is reported in the April 21, 2005 issue of The New England Journal of Medicine.

"Our study showed that both methotrexate and leflunomide can be used safely and effectively in children. In fact, in our study both drugs had a higher response rate in children than the response rate reported in studies in adults," said Dr. Silverman, the study’s lead author, a rheumatologist and senior associate scientist at Sick Kids, and a professor of Paediatrics at the University of Toronto. "A higher percentage of patients responded to methotrexate, so this would be the medication to try first in children, but leflunomide is a good alternative for patients where methotrexate doesn’t work or isn’t tolerated. Importantly, we have identified a new, safe, effective oral therapy for use in children with chronic arthritis."

The study also showed that a higher dose of methotrexate than previously thought can be used safely in children and that at the increased dose there was increased efficacy. Establishing drug dosages in children is more complicated than adults due to the wide variation in weight between a baby and a teenager.



Patients three to 17 years of age with polyarticular-course rheumatoid arthritis (where arthritis affects at least five joints) were recruited to the study at 32 centres in 13 countries. The children were given either methotrexate or leflunomide, medications that are DMARDs (disease-modifying anti-rheumatic drugs), which work by altering the immune system. Methotrexate is the most commonly used DMARD in children. DMARDs are a stronger class of arthritis medications than NSAIDs (nonsteroidal anti-inflammatory drugs).

"Most medications are never designed for children and are rarely tested in children. However, children do get severe arthritis that requires medications beyond NSAIDs. The only way to properly assess a medication for children is through a randomized, controlled trial. The ’Pediatric Rule’, enacted by the U.S. Congress and supported by the Food and Drug Administration (FDA), has increased the number of drug trials in children with arthritis," added Dr. Silverman.

Juvenile rheumatoid arthritis is a chronic disease that causes pain, stiffness and swelling in more than one joint. It affects approximately one out of every 1,000 Canadian children.

Laura Greer | EurekAlert!
Further information:
http://www.utoronto.ca

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>